LHLHHealthcare · Diagnostics & Research

LH Stock Forecast: Labcorp Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$368
−0.35% on the day

The 17 Wall Street analysts covering Labcorp Holdings, Inc. hold a median 12-month price target of $398 — +8.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 88 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$29.8B
Ticker Nerd rank
88/ 100
Median analyst target
$398
Analysts covering
17
Revenue$3.7B+5.8% y/y
Operating income$456.7M
Net income$299.1M
Free cash flow$313.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
+13.8%
YTD
+47.6%
1Y
+42.0%
From 52W high
−1.3%
From 52W low
+47.9%
$249
$372
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Labcorp Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
88/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Revisions
87
Momentum
86
Quality
76
Issuance
66
Growth
64
Value
63
Accruals
60

Volatility (98): The share price has been relatively steady.

Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Jan 26Apr 26Jul 26Oct 26LHHigh $420Median $398Low $347

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
13
Buy
4
Hold
0
Sell
$347
Low
$398
Median
$420
High

The green dot is the last close — the median target sits +8.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Oct 2026BairdMaintainsOutperform$361 → $396
29 Oct 2026BarclaysMaintainsEqual-Weight$330 → $380
29 Oct 2026Truist SecuritiesMaintainsBuy$365 → $395
29 Oct 2026UBSMaintainsBuy$380 → $420
21 Sept 2026Truist SecuritiesMaintainsBuy$350 → $365
11 Sept 2026BarclaysMaintainsEqual-Weight$320 → $330
11 Sept 2026UBSMaintainsBuy$361 → $380
4 Aug 2026Piper SandlerMaintainsNeutral$300 → $309
3 Aug 2026JP MorganMaintainsOverweight$330 → $360
31 July 2026BarclaysMaintainsEqual-Weight$290 → $320
31 July 2026Morgan StanleyMaintainsOverweight$308 → $338
31 July 2026Truist SecuritiesMaintainsBuy$320 → $350
13 July 2026B of A SecuritiesMaintainsBuy$300 → $320
13 July 2026BairdMaintainsOutperform$335 → $338
8 Apr 2026Evercore ISI GroupMaintainsOutperform—
24 Feb 2026Piper SandlerMaintainsNeutral—
18 Feb 2026BairdMaintainsOutperform—
18 Feb 2026JP MorganMaintainsOverweight—
6 Feb 2026JP MorganMaintainsOverweight—
7 Nov 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LH.

Market Radar

This page is one stock. Monday covers all of them.

LH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Labcorp Holdings, Inc. returned +42.0% against +6.9% for the S&P 500, dividends included.

LH vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26LHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+0.6%
Analysts raising
12
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.1×

Cheaper than 29% of US stocks

Price / sales
2.0×

Cheaper than 48% of US stocks

Price / book
3.4×

Cheaper than 27% of US stocks

EV / EBITDA
15.5×

Cheaper than 32% of US stocks

Growth & margins
Revenue growth (YoY)
6.9%

Higher than 46% of US stocks

Earnings growth (YoY)
0.7%

Higher than 37% of US stocks

Gross margin
29.8%

Higher than 34% of US stocks

Operating margin
11.2%

Higher than 65% of US stocks

Net margin
6.9%

Higher than 61% of US stocks

Returns & dividend
Return on equity
11.4%

Higher than 66% of US stocks

Return on assets
5.5%

Higher than 78% of US stocks

Dividend yield
0.8%

Higher than 14% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Labcorp Holdings, Inc. has a market value of $29.8B and an enterprise value of $36.4B.

  • Revenue in the twelve months to 30 June 2026: $14.3B. The latest quarter grew 5.8% year on year.

  • Net income over the same four quarters: $1.0B, a 7.0% net margin.

  • Diluted earnings per share, trailing twelve months: $12.09.

  • Free cash flow in the twelve months to 30 June 2026: $1.2B, after $483.2M of capital spending.

  • Labcorp Holdings, Inc. spent $701.8M on share buybacks and $239.1M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 80.9M.

  • Trailing P/E: 30.1×; forward P/E: 18.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.78%, paying out 24% of earnings.

  • Labcorp Holdings, Inc. employs 71,000 people — $202K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

LH and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
LHLabcorp Holdings, Inc.$29.8B88
ILMNIllumina, Inc.$29.1B95
DGXQuest Diagnostics, Inc.$28.7B93
MTDMettler-Toledo International, Inc.$34.1B96
NTRANatera, Inc.$39.6B70
IQVIQVIA Holdings, Inc.$40.5B83
WATWaters Corp.$43.2B52

Take a look at LH’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Labcorp Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LH

What is the LH stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Labcorp Holdings, Inc. have a median 12-month price target of $398, with estimates ranging from $347 to $420. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LH stock a buy right now?

Of the 17 analysts covering Labcorp Holdings, Inc., 13 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Labcorp Holdings, Inc. 88 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LH?

As at 21 Nov 2026, Labcorp Holdings, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will LH stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +8.1% from the last close, and Ticker Nerd's factor model ranks Labcorp Holdings, Inc. 88 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LH stock forecast for 2030?

No analyst covering Labcorp Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $347 to $420 over the next 12 months.

How has LH stock performed over the past year?

Labcorp Holdings, Inc. returned +42.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Labcorp Holdings, Inc. do?

Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development. Labcorp Holdings Inc. serves doctors, hospitals, pharmaceutical companies, researchers, and patients through a broad portfolio that includes routine and specialty diagnostic testing, central laboratory services, and early development research support.

Company

About Labcorp Holdings, Inc.

Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development. Labcorp Holdings Inc. serves doctors, hospitals, pharmaceutical companies, researchers, and patients through a broad portfolio that includes routine and specialty diagnostic testing, central laboratory services, and early development research support. Its Diagnostics Laboratories segment covers testing in areas such as oncology, women’s health, autoimmune disease, and neurology, while its Biopharma Laboratory Services segment supports pharmaceutical and biotech clients with laboratory capabilities for clinical trials and development programs. The company plays a key role in healthcare by helping customers generate data used in diagnosis, treatment decisions, and biomedical research.

CEO Mr. Adam H. Schechter · 71,000 employees · United States · https://www.labcorp.com